Skip to main content
Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc. — Investor Relations & Filings

Ticker · BOLT ISIN · US0977021049 LEI · 254900W0P77PQ6B8OY50 US Manufacturing
Filings indexed 269 across all filing types
Latest filing 2024-07-03 Regulatory Filings
Country US United States of America
Listing US BOLT

About Bolt Biotherapeutics, Inc.

https://boltbio.com/

Bolt Biotherapeutics is a clinical-stage biotechnology company developing immuno-oncology therapies to treat cancer. The company's approach leverages the innate immune system, particularly myeloid cells, to create a therapeutic anti-tumor response. Its proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) platform combines tumor-targeting antibodies with immune-stimulating agents. This technology is designed to repolarize tumor-supportive immune cells, such as macrophages, into tumor-destructive ones, while also activating the adaptive immune system. The company's pipeline includes multiple candidates generated from the ISAC platform and other novel approaches. A key candidate, BDC-3042, is a first-in-class Dectin-2 agonist antibody being evaluated in clinical trials.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2024-07-03 English
4
Director's Dealing
2024-06-15 English
4
Director's Dealing
2024-06-15 English
4
Director's Dealing
2024-06-15 English
4
Director's Dealing
2024-06-15 English
4
Director's Dealing
2024-06-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.